![](https://investorshub.advfn.com/uicon/48355.png?cb=1551739062)
Tuesday, October 05, 2021 8:13:57 AM
8:02 am ET October 5, 2021 (Newsfile) Print
Data Shows Statistically Significant Improvements in Speed and Motor Function in PD Patients
Annovis Bio to Request Meeting with FDA on Next Steps in Clinical Development
Investor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ET
Berwyn, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 PD patients, which found that once-daily ANVS401 was superior to placebo in improving motor function.
The second part of the study expanded on the original 14 AD and 14 PD patients by recruiting an additional 40 PD patients for a total of 54 PD patients, who were treated with either 0mg, 5mg, 10mg, 20mg, 40mg or 80mg of ANVS401 once daily. Safety and two psychometric assessments - the coding test of the Wechsler Adult Intelligence Scale (WAIS) and the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) - were conducted at day 0 and day 25, comparing ANVS401-dosed PD patients with those dosed with placebo. ANVS401 has been found to be well-tolerated and safe with no adverse effects related to treatment observed.
When compared to the placebo group, statistically significant improvements in WAIS coding scores were observed in PD patients taking ANVS401 5mg, 20mg and 80mg once daily, highlighting increased motor-dexterity, as well as speed and accuracy compared to placebo (Figure 1). Further, PD patients taking ANVS401 5mg, 20mg and 80mg also achieved statistically significant improvements from baseline in the same test (Figure 1). PD patients treated with ANVS401 10mg and 20mg once daily showed statistically significant improvements in the UPDRS 2, 3, 4, and in total MDS-UPDRS test compared to baseline (Figure 2).
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7656/98604_abdd38ead4cc6899_002.jpg
Figure 1 - WAIS Coding Test Results for 54 PD Patients - Statistical significance from baseline is signified by an asterisk on the top of a dose bar; statistical significance from placebo is signified by an asterisk on a line from the placebo to a dose bar. Single asterisks represent p<0.05, while two asterisks represent p<0.01.
To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/7656/98604_abdd38ead4cc6899_002full.jpg
Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7656/98604_abdd38ead4cc6899_003.jpg
Figure 2 - MDS-UPDRS Total Results for 54 PD Patients - Patients dosed with 10mg and 20mg showed marked improvement when compared to baseline for motor control and function. Statistical significance from baseline is signified by an asterisk on the bottom of a dose bar. Single asterisks represent p<0.05.
To view an enhanced version of Figure 2, please visit:
https://orders.newsfilecorp.com/files/7656/98604_abdd38ead4cc6899_003full.jpg
This dosing study shows that ANVS401 is efficacious across the tested dose range when measured by WAIS coding and shows better efficacy around 10 to 20mg once per day when measured by MDS-UPDRS. This dose range provides guidance as to what doses to use in the upcoming phase 3 studies in AD and PD patients.
"We are thrilled by these improvements in motor function of PD patients. Through examination of this dose-response, we can determine an optimal safe and efficacious dose as we move forward towards initiation of Phase 3 clinical trials with much larger patient populations and longer timelines. These positive efficacy results, which expand on our previous data from AD and PD patients, add clarity to the benefits that ANVS401 may offer to patients suffering from these chronic neurodegenerative diseases," said Founder, President and CEO of Annovis, Maria L. Maccecchini, Ph.D. "We are still analyzing certain biomarker data from the 54 PD patients and will share the results when they are available. We will be asking the FDA for a meeting to receive guidance on next steps in clinical development in light of the AD/PD Phase 2 clinical results."
Annovis Bio will host an investor conference call today, October 5th, 2021, at 9:00 am ET. Interested parties can participate through the following link: https://russopr.zoom.us/j/87423723968
About WAIS and MDS-UPDRS Psychometric Assessments
The WAIS coding subtest measures visual-motor dexterity, associative nonverbal learning, and nonverbal short-term memory. It also measures fine-motor dexterity, speed, accuracy, and ability to manipulate a pencil and perceptual organization.
The MDS-UPDRS evaluates several motor and non-motor experiences specific to the progression of Parkinson's disease, including cognitive impairment, general mental state, facial expression, tremors, and other key features. The UPDRS is the current standard for clinical examination of patients diagnosed with PD.
About Annovis Bio, Inc.
Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We have two ongoing Phase 2 studies: one in AD patients and one in both AD and PD patients. In the AD/ PD study our drug improves memory loss and dementia associated with AD, as well as body and brain function in PD.
For more information on Annovis Bio, please visit the company's website: www.annovisbio.com
New York Yankees and Duke Basketball
Recent ANVS News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 10:05:38 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 09:00:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:32:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 08:05:24 PM
- Annovis Announces New Publication in a Peer-Reviewed Journal • GlobeNewswire Inc. • 05/21/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:05:46 PM
- Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/13/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:11:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:03:33 PM
- Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 09:12:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:11:19 PM
- Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders • GlobeNewswire Inc. • 05/06/2024 11:30:00 AM
- Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease • GlobeNewswire Inc. • 04/29/2024 02:10:00 PM
- Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/02/2024 11:30:00 AM
- US Stock Movers Before Market: Beyond Meat, eBay, First Solar, Urban Outfitters… • IH Market News • 02/28/2024 12:08:14 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/12/2024 07:00:23 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/01/2024 09:05:20 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:27:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 07:33:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 07:31:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 07:29:31 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM